Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Mr Michał Tendera
Dr. Mihai Gheorghiade
Presenter report:Gheorghiade, Mihai (United States of America)webcast
Patients admitted with Acute Heart Failure Syndromes (AHFS) have a post-discharge mortality and re-hospitalization that can be as high as 15% and 30%, respectively, within 60-90 days post-discharge. The clinical and laboratory profiles of these patients in the early post-discharge phase have not been well studied. Identifying potential targets for therapy during the immediate post-discharge period is important in order to reduce the high event rate. Objectives: The objectives of this retrospective analysis of prospectively collected data were 1) to establish the clinical, electrolyte, renal, hepatic, and neurohormonal profile post-discharge in patients who died or were re-hospitalized within 3 months, within 3-12 months, and those with no events at 1 year post-discharge, and 2) to determine the prognostic value of post-discharge clinical and laboratory parameters for mortality and readmission.
Methods: The EVEREST trial randomized 4133 patients admitted with worsening HF and an ejection fraction (EF) <40% to oral tolvaptan versus placebo in addition to standard therapy. Patients were followed for a median of 9.9 months. During hospitalization and post-discharge, the following parameters were collected prospectively on hospital day 1, day 7 or discharge, post-discharge weeks 1, 4, 8, and then every 8 weeks thereafter: blood pressure (BP), heart rate (HR), body weight, serum sodium, potassium, magnesium, blood urea nitrogen (BUN), creatinine, estimated glomerular filtration rate (eGFR), liver function and B-type natriuretic peptide (BNP) or N-terminal pro-BNP, aldosterone, arginine vasopressin (AVP). Results: Post-discharge signs and symptoms of HF resulting from abnormal hemodynamics, as well as neurohormonal and renal abnormalities appear to predict high early post-discharge mortality and re-hospitalization rates, in spite of evidence-based therapies (ACEI/ARB, BB, Aldosterone-blocking agents). In the multivariate time-dependent analysis, the major post-discharge predictor for early mortality was worsening renal function (change in BUN). An increase in body weight was the major predictor for early re-hospitalization. This data suggests new therapies aimed at safely improving hemodynamics, neurohormonal profile, and renal function are needed.
Discussant: Tendera, Michal (Poland)
Clinical Trial Update II